Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicals
The role of regulatory T-cells and IL-13 in the treatment of chronic inflammatory bowel diseases and intestinal fibrosis.
A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory Diseases
Accelerating the valorisation of the BEAT inflammation technology, a microbiome-based biotherapeutic for chronic respiratory inflammatory diseases.
Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases
Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases.